Drug Combination Details
| General Information of the Combination (ID: C01919) | |||||
|---|---|---|---|---|---|
| Name | Bufalin NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PLC/PRF/5 | CVCL_0485 | Adult hepatocellular carcinoma | Homo sapiens | ||
| SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | A total of 1*107 SMMC-7721 cells in a volume of 200 uL PBS were injected into the right flank of each mouse (6-week old male Balb/c nude mice weighing 20 g) to form subcutaneous tumors. | |||||
| Experimental
Result(s) |
The treatment of sorafenib combined with bufalin synergistically suppressed HCC proliferation and induced apoptosis. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ERK1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | PLC/PRF/5 | CVCL_0485 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. | |||||
| Experiment 3 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | PLC/PRF/5 | CVCL_0485 | Adult hepatocellular carcinoma | Homo sapiens | ||
| SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | A total of 5x106 SMMC-7721 cells in 0.2 ml phosphate-buffered saline (PBS) were injected into the right flank of each mouse (six-week old male Balb/c nude mice) to form subcutaneous tumors. | |||||
| Experimental
Result(s) |
Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. | |||||
| Experiment 4 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HUVEC | CVCL_2959 | Healthy | Homo sapiens | ||
| Experimental
Result(s) |
Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Bufalin reverses resistance to sorafenib by inhibiting Akt activation in hepatocellular carcinoma. | |||||
